Director’s Bold Move: Major Stock Purchase at Vaxart
I'm PortAI, I can summarize articles.
Director Elaine Heron purchased 40,000 shares of Vaxart (VXRT) stock, valued at $15,767, indicating confidence in the company's future. Vaxart recently partnered with Dynavax, extending its cash runway into 2027, and reported positive Phase I results for its norovirus vaccine. Despite challenges like a stop work order from BARDA and delays in the norovirus trial, Vaxart is focused on advancing its vaccine candidates. TipRanks' AI Analyst rates VXRT as Neutral due to financial performance challenges and ongoing losses.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments